Pipeline

Overview

Innovative pipeline development strategy

Differentiated R&D for Fast New Drug Success and Profitability

  • Pipeline
  • Indication
  • Route of
    Administration
  • Discovery
    Preclinical
    Phase Ⅰ

    Phase Ⅱ

    2a 2b

    Phase Ⅲ
    Launch
  • Diabetic Macular Edema
    Oral

    Phase 2a study (us) began in Oct 2022 / Topline data announced in Feb 2024
  • Wet-AMD(Age-related Macular Degeneration)
    Oral

    Completed phase 1 study (US) in Jun 2022
  • Ulcerative Colitis
    Oral

    Phase 2 study IND approval(US) in Jun 2023 / IND approval(Europe) in Dec 2023
  • Immuno-Oncology Combination
    Oral

    Completed phase 1 study (US) in Jun 2022
  • Psoriasis
    Topical

    Discovery
  • Next-Generation Endothelial Dysfunction Blocker
    Oral

    Discovery
  • Ulcerative Colitis
    Oral

    High dose Phase 1b study IND submission in Aug 2023
  • Immuno-Oncology Combination
    Oral

    High dose Phase 1b study IND submission in Aug 2023
  • Pipeline
  • Indication
  • Route of
    Administration
  • Discovery
    Preclinical
    Phase Ⅰ

    Phase Ⅱ

    2a 2b

    Phase Ⅲ
    Launch
  • Diabetic Nephropathy
    Oral

    Phase 2b first patient enrolled in Feb 2023
  • Wet-AMD(Age-related Macular Degeneration)
    Oral

    Finalized phase 2 CSR in Jan 2022
  • Cancer
    Oral

    Discovery
  • Cancer
    Oral

    Discovery